OUR MISSION

COMMUNITY RESEARCH INITIATIVE (CRI) is an independent, nonprofit, community-based organization dedicated to leading the way in HIV/AIDS and hepatitis C clinical research; ensuring access to lifesaving medications and health insurance coverage for Massachusetts residents in need who are HIV-positive, have tuberculosis, or who have other infectious diseases; and disseminating state-of-the-art treatment information and education about how to access and maintain health insurance and health benefits coverage for people in need.

We envision that safe and effective treatments and lifesaving drugs and health insurance are available to all people living with HIV/AIDS, hepatitis C, tuberculosis, and other infectious diseases.

CRI is proud to play a key role in the fight to end the HIV epidemic in Massachusetts and the United States. We closely align our efforts and focus with the statewide and national HIV/AIDS prevention and treatment strategies:

Massachusetts will be a place where HIV infections are rare, and when they occur, every state resident, regardless of age, gender, race/ethnicity, sexual orientation, gender identity, or socioeconomic status will have unfettered access to high quality, life-extending care, free from stigma and discrimination.

– MA Integrated HIV/AIDS Prevention and Care Plan; HIV/AIDS Services in the Commonwealth: 2017 -2021. Adapted from the National HIV/AIDS Strategy: Updated to 2020, Office of National AIDS Policy, The White House.

CRI's Mission in Action

IDDAP: As the administrator of the Massachusetts Infectious Disease Drug Assistance Program (IDDAP), CRI plays a vital role in helping people in Massachusetts access critical, lifesaving medications and health insurance coverage in an affordable manner.

  • HDAP helps people in need afford their HIV treatment. 
  • nPEP connects people who are HIV-negative to post-exposure prophylaxis.
  • PrEPDAP helps people who are HIV-negative pay for pre-exposure prophylaxis (PrEP).
  • CHII provides people living with HIV with affordable health insurance coverage.
  • TBDAP assists people with tuberculosis pay for and access treatment.

RESEARCH: CRI has conducted life-changing clinical research and contributed critical building blocks of research data that resulted in the FDA approval of nearly all the currently available HIV medications. CRI's researchers have presented key, groundbreaking data at national and international conferences, disseminating study results for these HIV drugs to researchers, advocates, medical providers, and people living with HIV across the world. As a result, nearly all people with HIV who have access to these drugs can live a normal life span. CRI has taken this finely tuned expertise and began investigating other infectious diseases including hepatitis C.

BRIDGE: CRI's BRIDGE Team expertly helps HIV + clients in need navigate the confusing array of health insurance options when they face barriers to the care that they need, including during the annual open enrollment period. BRIDGE Team members train case managers, providers, and HIV+ clients on accessing health care and insurance, determining appropriate levels of coverage, avoiding prohibitive out-of-pocket expenses, and retaining comprehensive coverage in a constantly changing insurance environment.